Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

This study has been completed.
Sponsor:
Collaborator:
Quintiles
Information provided by:
Pacgen Biopharmaceuticals Corporation
ClinicalTrials.gov Identifier:
NCT00659971
First received: March 18, 2008
Last updated: June 25, 2008
Last verified: June 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2008
  Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)